|
WO2021077105A1
|
|
Human periventricular endothelial cell therapy for neuropsychiatric disorders
|
|
WO2020237104A1
|
|
Autologous cell replacement therapy for parkinson's disease
|
|
US2020206309A1
|
|
METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS
|
|
US2019376046A1
|
|
Methods for manipulating cell fate
|
|
AU2016354447A1
|
|
Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
|
|
CA2977661A1
|
|
Methods and compositions for the treatment or prevention of parkinson's disease
|
|
WO2015073625A2
|
|
Synergistic genome-nonintegrating reprogramming by micrornas and transcription factors
|
|
WO2015070046A1
|
|
System and method for tracking cerebral blood flood flow in fmri
|
|
WO2015069736A1
|
|
METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
|
|
US2015306136A1
|
|
Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
|
|
US2013331394A1
|
|
Treating schizophrenia
|
|
WO2013152066A1
|
|
System and method for evaluation of circulatory function
|
|
EP2822936A2
|
|
Aminoquinoline derivatives and uses thereof
|
|
US2014235929A1
|
|
Magnetic field stimulation
|
|
EP2710124A1
|
|
Neuronal progenitor cells and uses
|
|
WO2012083128A2
|
|
Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
|
|
WO2012048330A2
|
|
Treatment of motor neuron disease
|
|
WO2011153521A2
|
|
Multi-modal imaging of blood flow
|
|
WO2011143534A1
|
|
Methods for the treatment of psychiatric disorders
|
|
WO2011130675A2
|
|
Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
|
